Symbols

CRVO

CervoMed·NASDAQ

--(--)

Signals Analysis

Bullish signal 5

Bearish signal 0

Consensus Rating "Strong Buy"

Ample Liquidity

High Gross Profit Margin

Revenue Beats Expectation

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About CRVO

Cervomed Inc.

A company that developing standard-of-care therapies for treatment-resistant solid cancerous tumors

Industry

Biological Technology

Established Date

01/10/1995

Listing Date

11/09/2016

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.cervomed.com

Security Type

Common stock

Office address

20 Park Plaza, Suite 424, Boston, Massachusetts 02116

Business

Introduction

CervoMed Inc., was originally incorporated under the laws of Nevada on January 10, 1995 and re-incorporated in Delaware on June 18, 2015. The company is a clinical-stage biotechnology company focused on developing treatments for age-related neurological diseases. Their lead drug candidate, neflamapimod, is an oral small molecule drug in development that can easily cross the blood-brain barrier and selectively inhibit the enzyme p38α, a key driver of neuroinflammation and synaptic dysfunction. By targeting key pathological processes in brain degenerative diseases, neflamapimod is expected to reverse synaptic dysfunction, improve neuronal health, and delay or stop disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies (DLB), its main indication, as well as non-fluent primary progressive aphasia (nfvPPA), rheumatoid arthritis (RAS) and amyotrophic lateral sclerosis (ALS).

Company Financials

EPS

CRVO has released its 2025 Q3 earnings. EPS was reported at -0.84, versus the expected -0.61, missing expectations. The chart below visualizes how CRVO has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

CRVO has released its 2025 Q4 earnings report, with revenue of 8.73K, reflecting a YoY change of -99.60%, and net profit of -8.09M, showing a YoY change of -20.60%. The Sankey diagram below clearly presents CRVO's revenue sources and cost distribution.